EastWest Bioscience Past Earnings Performance
Past criteria checks 2/6
EastWest Bioscience has been growing earnings at an average annual rate of 14.2%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 30.8% per year.
Key information
14.2%
Earnings growth rate
27.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 30.8% |
| Return on equity | -0.02% |
| Net Margin | 15.4% |
| Last Earnings Update | 30 Apr 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How EastWest Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 22 | 1 | 0 | 3 | 0 |
| 31 Jan 22 | 1 | 1 | 3 | 0 |
| 31 Oct 21 | 1 | -2 | 2 | 0 |
| 31 Jul 21 | 1 | -2 | 2 | 0 |
| 30 Apr 21 | 1 | -1 | 1 | 0 |
| 31 Jan 21 | 1 | -1 | 2 | 0 |
| 31 Oct 20 | 1 | -1 | 2 | 0 |
| 31 Jul 20 | 1 | -1 | 2 | 0 |
| 30 Apr 20 | 2 | -2 | 2 | 0 |
| 31 Jan 20 | 2 | -3 | 3 | 0 |
| 31 Oct 19 | 2 | -3 | 3 | 0 |
| 31 Jul 19 | 1 | -4 | 3 | 0 |
| 30 Apr 19 | 1 | -4 | 3 | 0 |
| 31 Jan 19 | 1 | -4 | 3 | 0 |
| 31 Oct 18 | 0 | -4 | 2 | 0 |
| 31 Jul 18 | 0 | -3 | 2 | 0 |
| 30 Apr 18 | 0 | -2 | 1 | 0 |
| 31 Jan 18 | 0 | -1 | 1 | 0 |
| 31 Oct 17 | 0 | -1 | 1 | 0 |
| 31 Jul 17 | 0 | -1 | 1 | 0 |
| 30 Apr 17 | 0 | -1 | 0 | 0 |
| 31 Jan 17 | 0 | -1 | 0 | 0 |
| 31 Oct 16 | 0 | 0 | 0 | 0 |
| 31 Jul 16 | 0 | 0 | 0 | 0 |
Quality Earnings: EAST has a large one-off gain of CA$3.5M impacting its last 12 months of financial results to 30th April, 2022.
Growing Profit Margin: EAST became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EAST has become profitable over the past 5 years, growing earnings by 14.2% per year.
Accelerating Growth: EAST has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: EAST has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: EAST's Return on Equity (-0.02%) is considered low.